Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens
Haematologica. 2024 Apr 24. doi: 10.3324/haematol.2024.285225. Online ahead of print.ABSTRACTIn newly diagnosed acute myeloid leukemia, immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pre-therapeutic risk factors. We explored the impact of time from diagnosis to treatment on outcomes in newly diagnosed acute myeloid leukemia undergoing venetoclax-based therapy in two distinct cohorts. By querying the Study Alliance Leukemia database and the global health network TriNetX, we identified 138 and 717 patients respectively with an average age of 76 and 72 years who received venetoclax-based firstline therapy. When comparing patients who started treatment earlier or later than 10 days after initial diagnosis, no significant difference in median overall survival was observed - neither in the SAL cohort (7.7 vs. 9.6 months, p=.42) nor in the TriNetX cohort (7.5 vs. 7.2 months, p=.41). Similarly, severe infections, bleeding, and thromboembolic events were equally observed between early and later treatments, both in the overall patient groups and specific subgroups (age ≥75 years or leukocytes ≥20x109/L). This retrospective analysis indicates that delaying the start of venetoclax-based therapy in newly diagnosed acute myeloid leukemia might be a safe option for selected patients, provided that close clinical monitoring is performed.PMID:38654660 | DOI:10.3324/haematol.2024.285225
Source: Haematologica - Category: Hematology Authors: David Baden Sven Zukunft Gema Hernandez Nadine Wolgast Sophie Steinhauser Alexander Pohlmann Christoph Schliemann Jan-Henrik Mikesch Bjorn Steffen Tim Sauer Maher Hanoun Kerstin Schafer-Eckart Stefan W Krause Mathias Hanel Hermann Einsele Edgar Jost Tim H Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bleeding | Databases & Libraries | Hematology | Leukemia | Study